Viatris Inc. (MYL.VI)
| Previous Close | 13.42 |
| Open | 13.42 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 13.42 - 13.42 |
| 52 Week Range | 8.19 - 13.42 |
| Volume | |
| Avg. Volume | 61 |
| Market Cap | 7.395B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 26.01 |
| EPS (TTM) | N/A |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireViatris to Report First Quarter 2024 Financial Results on May 9, 2024
Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.
PR NewswireViatris Appoints Corinne Le Goff as Chief Commercial Officer
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.
CNW GroupViatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the launch in Canada of PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of Teva's Copaxone® 20 mg/mL, indicated for the treatment of patients with Relapsing-Remitting Multiple Sclerosis (RMMS), a chronic inflammatory disease of the central nervous system.
